Results 161 to 170 of about 107,749 (252)

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Janus kinase 1 inhibitors for treating immune checkpoint inhibitor-induced enterocolitis - report of two filgotinib-treated cases and literature review. [PDF]

Acta Oncol
Ekedahl H, Sigurjonsdottir G, Bergqvist V, Båtshake B, Carneiro A, Marsal J.   +5 more
europepmc   +1 more source

Circular RNA PIP5K1A act as microRNA-552-3p sponge to regulates inflammation, oxidative damage in glucolipotoxicity-induced pancreatic INS-1 β-cells via Janus kinase 1. [PDF]

Bioengineered, 2022
Ren L.
europepmc   +1 more source

Non‐Invasive Scalp Tape‐Strip RNA Sequencing Captures Disease Activity and Treatment‐Response Signatures in Alopecia Areata

Allergy, EarlyView.
Non‐invasive scalp tape‐strip RNA sequencing captures core immune and follicular molecular signatures in alopecia areata. Tape‐strip transcriptomic profiles reflect disease severity and treatment response to baricitinib, with concordance to scalp biopsy‐derived signatures.
Carmen Mochón‐Jiménez, Jesús Gay‐Mimbrera, Viviana Dávila‐Flores, Helen He, Jerry Zhou, Irene Rivera‐Ruiz, Pedro J. Gómez‐Arias, Juan de Luque‐Fernández, Benjamin Ungar, Emma Guttman‐Yassky, Juan Ruano   +10 more
wiley   +1 more source

Early Epidemiologic and Immune Predictors of Atopic Dermatitis: Reduced Cord Blood Regulatory B10 Cells in the Munich Atopy Prediction Study (MAPS)

Allergy, EarlyView.
In this prospective birth cohort from Munich, comprehensive clinical assessments and longitudinal lifestyle questionnaires were combined with cord blood immune profiling. Infants who later developed AD showed altered cord blood immune signatures, including reduced CD4+ T cells, increased B cells and markedly decreased Breg cells. Epidemiologic factors,
S. Preis, S. Kaesler, M. Koeberle, M. Hils, B. Evers, R. L. Silva, Y. Skabytska, L. Schellenberger, H. Hufnagel, M. Schielein, B. Kuschel, Y. Amar, A. Zink, T. Biedermann, Z. Kurgyis   +14 more
wiley   +1 more source

Cardiomyocyte Janus kinase 1 (JAK1) signaling is required for cardiac homeostasis and cytokine-dependent activation of STAT3. [PDF]

J Mol Cell Cardiol
Subramani A, Essandoh K, Young MY, Marino FH, Teuber JP, Wagner KU, Brody MJ.   +6 more
europepmc   +1 more source

Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial. [PDF]

Am J Clin Dermatol, 2021
Zhao Y, Zhang L, Ding Y, Tao X, Ji C, Dong X, Lu J, Wu L, Wang R, Lu Q, Goh AH, Liu R, Zhang Z, Zhang J.   +13 more
europepmc   +1 more source

Effect of JAK inhibitors on release of CXCL9, CXCL10 and CXCL11 from human airway epithelial cells [PDF]

, 2015
Barnes, PJ, Donnelly, LE, Fenwick, PS, Macedo, P   +3 more
core   +1 more source

A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome

British Journal of Haematology, EarlyView.
Fostamatinib had 46% durable response, with 73% steroid reduction, in this multicentre retrospective study of refractory wAIHA/ES. Hypertension, gastrointestinal (GI) distress and neutropenia occurred in 23%. Only one patient required drug discontinuation and one patient dose reduction.
Jorge N. Ruiz Lopez, Lipei Shao, Debbie Jiang, Lawrence S. Bailey, Thejaswi Bikkani, Aaron Boothby, Donald C. Moore, Irina Murakhovskaya, Caroline I. Piatek, Mauricio Pineda‐Roman, Ping Jin, Jacqueline N. Poston, Moritz Stolla, David F. Stroncek, Krystalyn E. Hudson, James B. Bussel, Sandhya R. Panch   +16 more
wiley   +1 more source

Efficacy and safety of Janus kinase 1/2 inhibitor KL130008 in active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase II trial. [PDF]

BMC Med
Cheng Y, Tang H, Qing Y, Liu Y, Yang L, Dang W, Yu J, Li R, Liu H, Jiang Z, Sun H, Yin S, Cheng J, Li Z, Fan W, Zhang H, Du H, Fu Z, Ma X, Wu J, Duan L, Zhang R, Lin J, Da Z, Wei W, Zhai Q, Wu B, Yi X, Jin X, Ge J, Feng P, Liu Y.   +31 more
europepmc   +1 more source